Skip to main content
. 2018 Apr 27;9(10):1863–1869. doi: 10.7150/jca.24950

Fig 3.

Fig 3

Fig 3

(a) Kaplan-Meier survival analysis for progression-free survival 1 (PFS1) after initial crizotinib treatment prior to RECIST-defined progressive disease (PD). The median PFS1 was 9.6 months (95% CI, 5.6-13.6 months). (b) Kaplan-Meier survival analysis for progress-free survival 2 (PFS2) after continuing ALK/ROS1 inhibition with crizotinib beyond PD. The median PFS2 was 5.9 months (95% CI, 0.1-11.7 months). Tick marks represent censored observations.